Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study
- First Online:
- 184 Downloads
Search for safe and effective strategies to diminish weight gain associated with second generation antipsychotics (SGAs) is imperative. In the present study, we sought to replicate our preliminary findings, which indicated that coadministration of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain.
Materials and method
Fifty-nine patients hospitalized for first-episode DSM-IV schizophrenic disorder participated in this randomized double-blind study. Reboxetine (4 mg/day; 31 patients) or placebo (29 patients) was coadministered with olanzapine (10 mg/day) for 6 weeks. Analysis was by intention-to-treat.
Nine patients in each group prematurely discontinued the trial. Olanzapine/reboxetine-treated patients showed a significantly lower increase in body weight (mean = 3.31 kg, SD = 2.73) than their olanzapine/placebo-treated counterparts (mean = 4.91 kg, SD = 2.45). Significantly fewer olanzapine/reboxetine-treated patients gained at least 7% of their initial weight, the cutoff for clinically significant weight gain (6 [19.4%] of 31 patients vs 13 [46.4%] of 28 patients). Seven (22.6%) olanzapine/reboxetine-treated patients compared to only one patient (3.6%) in the olanzapine/placebo group revealed no weight change or even modest weight loss. Appetite increase was significantly lower in the olanzapine/reboxetine than olanzapine/placebo group and was correlated with attenuation of weight gain. Reboxetine addition was safe and well tolerated.
The results confirm that coadministration of reboxetine promotes a clinically meaningful attenuation of olanzapine-induced weight gain in schizophrenia patients. If substantiated in long-term studies, along with behavioral management and diet counseling, reboxetine may have a clinical utility in controlling SGA-induced weight gain.
KeywordsSecond generation antipsychotics Olanzapine Reboxetine Weight gain
- Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa CityGoogle Scholar
- Andreasen NC (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa CityGoogle Scholar
- First MB, Spitzer RL, Gibbon M (1995) Structured clinical interview for DSM-IV Axis I disorders, Patient Edition (SCID-I/P, version 2.0). Biometric Research, New York State Psychiatric Institute, New York, NYGoogle Scholar
- Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055–1057PubMedCrossRefGoogle Scholar
- Guy W (1976) ECDE assessment manual for psychopharmacology. Revised DHEW Pub (ADM). National Institute of Mental Health, Rockville, MDGoogle Scholar
- Kanders BS, Forse RA, Blackburn GL (1991) Methods in obesity. In: Rakel RE (ed) Conn’s current therapy. WB Saunders, Philadelphia, pp 524–532Google Scholar
- Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C (2006) Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 67:547–553PubMedCrossRefGoogle Scholar
- Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl):11–19Google Scholar